Effects of anti-IL-5 monoclonal antibody on the murine model of nasal allergy

被引：19
|
作者：
Asakura, K [1 ]
Saito, H [1 ]
Watanabe, M [1 ]
Ogasawara, H [1 ]
Matsui, T [1 ]
Kataura, A [1 ]
机构：
[1] Sapporo Med Univ, Dept Otolaryngol, Chuo Ku, Sapporo, Hokkaido 060, Japan
来源：
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY | 1998年 / 116卷 / 01期
关键词：
nasal allergy; anti-IL-5 monoclonal antibody; murine model;
D O I：
10.1159/000023924
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
IL-5 is known to be closely related to the infiltration, activation and proliferation of eosinophils. In this study, we evaluated the in vivo effects of anti-IL-5 monoclonal antibody (mAb) in the murine model of nasal allergy. The mAb treatment inhibited the antigen-induced late phase eosinophilia, but had no effects on the number of basophilic cells. It also inhibited early phase nasal symptoms, and tended to inhibit histamine hypersensitivity. These findings suggest that IL-5 plays an important role in the pathogenesis of allergic nasal disorders.
引用
收藏
页码：49 / 52
页数：4
相关论文
共 50 条
  • [1] Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma
    Shardonofsky, FR
    Venzor, J
    Barrios, R
    Leong, KP
    Huston, DP
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (01) : 215 - 221
  • [2] Mepolizumab, a humanised anti-IL-5 monoclonal antibody, as treatment of severe nasal polyposis
    Gevaert, P.
    van Bruaene, N.
    Blomme, K.
    Sousa, A. R.
    Marshal, R. P.
    Bachert, C.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (03) : 797 - 797
  • [3] Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma
    Kupczyk, Maciej
    Kuna, Piotr
    IMMUNOTHERAPY, 2018, 10 (05) : 349 - 359
  • [4] Anti-IL-5 in the treatment of nasal polyps
    Kowalski, Marek L.
    CURRENT ALLERGY AND ASTHMA REPORTS, 2007, 7 (03) : 195 - 196
  • [5] Mepofizumab - 240563, Anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563
    不详
    DRUGS IN R&D, 2008, 9 (02) : 125 - 130
  • [6] Mepolizumab: 240563, Anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563
    不详
    Drugs in R & D, 2008, 9 (2) : 125 - 130
  • [7] INVOLVEMENT OF IL-5 IN A MURINE MODEL OF ALLERGIC PULMONARY INFLAMMATION - PROPHYLACTIC AND THERAPEUTIC EFFECT OF AN ANTI-IL-5 ANTIBODY
    KUNG, TT
    STELTS, DM
    ZURCHER, JA
    ADAMS, GK
    EGAN, RW
    KREUTNER, W
    WATNICK, AS
    JONES, H
    CHAPMAN, RW
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (03) : 360 - 365
  • [8] Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis
    Oldhoff, JM
    Darsow, U
    Werfel, T
    Katzer, K
    Wulf, A
    Laifaoui, J
    Hijnen, DJ
    Plötz, S
    Knol, EF
    Kapp, A
    Bruijnzeel-Koomen, CAFM
    Ring, J
    de Bruin-Weller, MS
    ALLERGY, 2005, 60 (05) : 693 - 696
  • [9] Mepolizumab. Humanized anti-IL-5 monoclonal antibody, Treatment of hypereosinophilic syndromes
    Revill, P.
    Mealy, N.
    DRUGS OF THE FUTURE, 2007, 32 (10) : 868 - 873
  • [10] Mepolizumab. Anti-IL-5 monoclonal antibody therapy in patients with Severe Eosinophilic Asthma
    Buttler, Bogna
    Dewor, Robert
    ALERGIA ASTMA IMMUNOLOGIA, 2018, 23 (03): : 137 - 142
12345